This article is more than 5 years old. Information may no longer be current.
Dana-Farber Cancer Institute names new president, CEO
Click Here to Manage Email Alerts
Laurie H. Glimcher, MD, has been named president and CEO of Dana-Farber Cancer Institute.
Glimcher, who also will serve as professor of medicine at Harvard Medical School, will assume her new roles in January 2017.
Laurie H. Glimcher, MD
“Dr. Glimcher is, in many ways, an ideal choice for Dana-Farber,” Josh Bekenstein, chairman of Dana-Farber Cancer Institute’s board of trustees, said in a press release. “She is a distinguished immunologist, widely renowned for her work in one of the most promising areas of cancer research. She has had extraordinary success as the leader of a major academic medical institution. Most importantly, she has a deep understanding of the latest developments in cancer research and care, and a clear vision of how Dana-Farber can most powerfully affect the fight against cancer.”
Glimcher currently serves as Stephen and Suzanne Weiss dean of the Medical College at Weill Cornell Medicine. She also is professor of medicine and provost for medical affairs at Cornell University.
Prior to joining Weill Cornell Medicine, she served as professor of immunology at Harvard School of Public Health, as well as professor of medicine at Harvard Medical School.
She is regarded for her understanding of cellular differentiation pathways in lymphocytes. She also made several discoveries of key transcription factors that drive lineage commitment and activation in the immune system.
“It is an enormous honor and privilege to be chosen as the next leader of Dana-Farber Cancer Institute,” Glimcher said in the release. “The opportunity to advance Dana-Farber's groundbreaking research and to improve the care available to patients with cancer is truly special to me, and I am thrilled to be returning home to Boston. Cancer research and care have reached a transformative moment in science, and I look forward to working with all of Dana-Farber's clinicians and scientists to find innovative therapies in the coming years.”